The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Jan. 24, 1:20 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #82. Adamis Pharmaceuticals Dry Powder Inhaler Technology From 3M Company

Acquirer: Adamis Pharmaceuticals (ADMP)
Acquiree: Dry Powder Inhaler Technology From 3M Company (MMM)
Details: Adamis Pharmaceuticals Corporation (OTCQB: ADMP) announced today that it has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Company's (NYSE: MMM) Taper Dry Powder Inhaler (DPI) technology under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As a part of the agreement, Adamis will obtain worldwide rights to use this platform technology in all indications in the dry powder inhalation field. The unique design uses proprietary 3M technology to store active pharmaceutical ingredient (API) on a microstructured carrier tape. 3M will supply the drug delivery tape for the platform to Adamis under a separate supply agreement. 3M Drug Delivery Systems is a pioneer in the area of novel inhalation drug delivery technology and has more than 50 years of experience and proven success in the field.

Adamis Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, respiratory and inflammatory disease. Co.'s products and product candidates include: Symjepi (epinephrine) Injection 0.3mg for use in the treatment of acute allergic reactions, including anaphylaxis; SYMJEPI (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis for patients weighing 33 to 65 pounds; a naloxone injection product candidate ZIMHI for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-1000) for the treatment of asthma.

Open the ADMP Page at The Online Investor »

Adamis Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, respiratory and inflammatory disease. Co.'s products and product candidates include: Symjepi (epinephrine) Injection 0.3mg for use in the treatment of acute allergic reactions, including anaphylaxis; SYMJEPI (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis for patients weighing 33 to 65 pounds; a naloxone injection product candidate ZIMHI for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-1000) for the treatment of asthma.

Open the MMM Page at The Online Investor »

Company Name: 
Adamis Pharmaceuticals Corp.
Website: 
www.adamispharmaceuticals.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding ADMP: 
3
Total Market Value Held by ETFs: 
$3.78M
Total Market Capitalization: 
$91.00M
% of Market Cap. Held by ETFs: 
4.15%
Company Name: 
3M Co
Stock buyback: 
MMM buyback
Website: 
www.3M.com
Sector: 
Medical Instruments & Supplies
Number of ETFs Holding MMM: 
133
Total Market Value Held by ETFs: 
$13.77B
Total Market Capitalization: 
$102.85B
% of Market Cap. Held by ETFs: 
13.39%
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 82 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.